Clinical Scorecard: Long-Term Outcomes of Autologous Stem Cell Transplantation for Pediatric Solid Tumors in a Resource-Constrained Environment: Insights from a 15-Year Single-Center Study

At a Glance

Key Highlights

• 3-year overall survival (OS) of 50.6% for the entire cohort (source needed).
• Median age of patients was 6 years, with 69.6% being male (source needed).
• High-risk neuroblastoma (HRNB) had a 3-year OS of 48.5% (source needed).
• Relapsed/refractory Ewing sarcoma (EWS) had a 3-year OS of 43.8% (source needed).
• BuMel-140 conditioning regimen showed better OS than CEM-200 for HRNB and EWS (source needed).

Guideline-Based Recommendations

Diagnosis

• Diagnosis includes high-risk neuroblastoma, relapsed/refractory Ewing sarcoma, relapsed/refractory germ-cell tumors, retinoblastoma, and soft-tissue sarcoma (source needed).

Management

• ASCT is indicated after achieving at least a partial response to induction therapy for HRNB (source needed).

Monitoring & Follow-up

• Monitor engraftment kinetics and transplant-related toxicity (source needed).

Risks

• Higher transplant-related mortality due to infection-related complications in LMICs (source needed).

Patient & Prescribing Data

Children, adolescents, and young adults (CAYA) aged ≤25 years

Median CD34+ cell dose was 5.7 million/kg with a median cryopreservation duration of 16 days

Clinical Best Practices

• Utilize supportive care including preemptive transfusions and prophylactic antimicrobials (source needed).
• Select conditioning regimens based on disease-specific risk stratification and chemosensitivity (source needed).

Related Resources & Content

• Study on ASCT outcomes